Good tolerance & safety
French Competent Authority (ANSM), June 18, 2013, the local Ethic Committee (CPP) cleared a new amendment of DRIIM trial for up to 2 dose expansion cohorts at the recommended dose as a results of good tolerance and safety, as well as the observed tumor responses correlated with systemic exposure of DT01.